• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Cigna Leverages AI


Why and how the insurance giant is getting into the AI space.

Binary Data

Cigna is tapping into artificial intelligence (AI) to solve some of healthcare’s most crucial problems and to further advance whole person health for its customers and clients.

Cigna Ventures, Cigna's corporate venture fund, led a $23 million Series D fundraising round in GNS Healthcare, a precision medicine company with an AI platform that turns millions of data streams into personalized insights to precisely match the appropriate treatment intervention to the right patient at the right time.

Cigna Ventures is actively focused on identifying, assessing and sponsoring early-stage innovative companies that warrant deeper exploration through focused proofs of concept, pilot, and scaled launches in three core areas:

  • Insights and Analytics

  • Digital Health and Retail

  • Care Delivery/Management

GNS is the first insights/analytics-focused investment Cigna Ventures has announced since the $250M fund launch in September 2018-adding to Prognos, a data-rich AI company that provides health monitoring platforms to track and predict disease.

Related: The Future Of AI In Cancer Care

“The addition of GNS will complement, enhance and further expand Cigna’s advanced analytics capabilities and our portfolio,” says Tom Richards, senior vice president and global lead, strategy & business development at Cigna. “Cigna’s goal is to collaborate with GNS to combine respective data and advanced analytics and machine learning capabilities which will strengthen Cigna’s clinical care programs‑improving predictability and personalized interventions to drive better outcomes. The addition of GNS will also complement, enhance, and further expand Cigna’s advanced analytics capabilities across the company and within the Cigna Ventures portfolio.”

According to Richards, deep partnerships with companies like GNS can accelerate our ability to bring more personalized, outcomes-focused solutions to market faster to address whole person health.

“Healthcare executives are looking to improve care quality and affordability for their customers, we believe precision medicine is part of this component,” Richards says. “GNS’s AI technology transforms data to precisely match therapeutics, procedures, and care management interventions to individuals to help improve health outcomes.”

Cigna Ventures is in the early stages of partnership and exploration with GNS so there are no immediate changes to their clinical care offerings. However, oncology is among the first key target areas. 

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.